ANP presenting now, page-118

Well,no stress! Deal/no deal, partnership/no partnership…

Wejust to have be patient and TRUST the wisdom of the management board to thinkwhat is best for the company overall and what is the true value our shareholdersdeserve.

Hopefullya positive newsflow from next indication this coming week…

AsMark mentioned in the recent presentation (Hidden Gems Webinar Presentation on05-02-2021), that will be something like muscular dystrophy.

Pointstaken from the presentation:

1) Initial focus on rare diseases space where there’re no effective therapy.

2) Benefit from the incentive regulatory authority provided to go into rarediseases

3) Lookfor premium pricing

4) Withlittle/no competition

Hementioned 3 times about the indications (like Duchenne (HINT!) - sound easyjust like ‘copy and paste’). So, any form of muscular dystrophies can happened here: Becker, Limb-girdle, Myotonic, Congenital etc.

Note: Sarepta is currently developing Limb-girdle.

Ifyou recall Dr. Gil Price recently attended both

1. Jett Foundation 4^th Annual Rare Disease Day (Jett Foundation aims to extend and enrich the lives of individuals affected by Duchenne muscular dystrophy(DMD) and other neuromuscular disorders.

2. FDA Rare Disease Day 2021 -The conference is organized by the FDA Office of Orphan Products Development, whose mission is to advance the evaluation anddevelopment of products (drugs, biologics, devices, or medical foods) thatdemonstrate promise for the diagnosis and/or treatment of rare diseases orconditions.

Thepurpose of this meeting is for the FDA to highlightstrategies to support rare disease product development… the importance ofpatient engagement and natural historystudies in rare disease product development, strategies to support rare diseaseproduct development…

Mark Diamond CEO of AntisenseTherapeutics said: ”The FDA Rare Disease Day presents an opportunity for us to gain additional insights from the rare diseasecommunity….”

Justto recap the following from (AGM Presentation 2020 – Next steps):

“Alsothe broader effects of CD49d modulation by ATL1102 are to be studied by analyzing DMD patient plasma samples to identify potential additional immune modulation mechanisms that may be relevant in the treatment of other diseases with this experimental work scheduled for1H 2021”

“The funds from the recent capital raising nowallow for the above work to be undertaken the results of which areanticipated to add further value to the ATL1102 asset."

...So, I guess we don’t need any more funds for that?


Remember Dr. Charmaine Gittleson came from Blood products giant CSL…

Dr. Charmaine Gittleson… “…achieving five new major global product approvals and launches within a 24-month period, which included a number of rare disease therapies.”…. Dr Gittleson added “I am thrilled to be joining the Antisense Therapeutics Board at this key juncture in the development pathway of ATL1102. My corporate career has been dedicated to working in rare diseases and the communities and being able to continue contributing, now to the Duchenne’s community with a novel and robust scientific approach is inspiring.”

Ifyou also refer to Corporate Connect research report dated 16-10-2020 which inline with Mark’s Diamond told us: OPPORTUNITIES ARE ABUNDANT!!

“Therole of inflammation in many diseases is only now being truly understood. The obvious next indications to trial ATL1102 arethe other muscular dystrophies, which add another 125k patientsto ATL1102’s ultimate applicable market.The molecule ATL1102 targets is also implicated in other diseases, providing opportunitiesbeyond the muscular dystrophies and, if fleshed out, an even stronger reason for larger biopharmaceutical companies to look at Antisense. “

"It looks like the door is now wide openfor Antisense to make its mark in drug development. Most importantly forinvestors, that means value creation can start to ramp up at incredible rates”

Ifthere is an announcement other than muscular dystrophy like inflammatorydiseases (Rheumatoid arthritis, Asthma, Alzheimer and etc) OR perhaps Spinal Muscular Atrophy and Amyotrophic LateralSclerosis (ALS) are also part of the neuroimmunologic disorders, then that will beBONUS to me!

Let's see whether the new indications will bring any "favorable" factor to the market... If others believe the new indications will bring the value/asset to the company, I'm sure the wave of buying pressure will cause the share price to rise.... We wait...